ETF (UCITS compliant)

L&G Pharma Breakthrough UCITS ETF

Fund facts

Fund size*
Base currency
Listing date
23 Jan 2018
Index ticker
Replication method
Physical - backed by equities


*As at 21 Oct 2020

Fund aim

The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").

  • Long-term allocation

Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives

  • High growth potential

Aims to capture the future growth opportunity in orphan drugs

  • Leveraging industry expertise

An index tracking investment strategy that is supported by a team of pharmaceutical experts

Solactive Biotechnology Breakthrough Value Index

The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently “liquid” (a measure of how actively its shares are traded on a daily basis).

The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.

Index data

Bloomberg code
Reuters code
Net Total Return

Fund updates


Source: Lipper.

Performance (%)
Select period:

    Performance summary (%)

    As at 30 Sep 2020

    1 month-1.52-1.42
    6 months31.1831.55
    Year to date19.6120.06
    3 years--
    5 years--
    Since launch20.1422.27
    1 year40.0540.80
    3 years--
    5 years--
    Since launch7.077.77

    As at 30 Sep 2020

    Year to date19.6120.06
    3 years--
    5 years--
    Since launch20.1422.27
    1 year40.0540.80
    3 years--
    5 years--
    Since launch7.077.77
    Rolling 12-month performance
    Calendar year performance
    Monthly performance
    Annualised performance

    Rolling 12-month performance to last quarter end (%)

    12 months to 30 September 2016 2017 2018 2019 2020

    Calendar year performance (%)

    2015 2016 2017 2018 2019

    Monthly performance (%)

    Annualised performance (%)

    1 year3 years5 yearsSince launch

    Annualised performance (%)

    1 year3 years5 yearsSince launch

    Performance for the USD Accumulating ETF class in USD, listed on 23 January 2018. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

    Past performance is not a guide to the future.


    As at 30 Sep 2020. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding.

    The breakdowns below relate to the Index. The ETF’s portfolio may deviate from the below

    Sector (%)

    Health Care96.7
    Precision Medicine3.3

    Currency (%)

    Top 10 constituents36.0
    Rest of Index64.0
    No. of constituents in Index30

    Top 10 constituents (%)

    Seattle Genetics4.2
    Swedish Orphan Biovitrum3.6
    Basilea Pharmaceutica3.5
    Horizon Therapeutics3.5
    Torii Pharmaceutical3.5
    Ultragenyx Pharmaceutical3.5
    Jazz Pharmaceuticals3.5
    Kyowa Kirin3.4
    Sarepta Therapeutics3.4

    Investment Manager

    GO ETF Solutions LLP is the investment manager for each of the exchange traded funds (ETFs) issued by Legal & General UCITS ETF Plc and is responsible for the day-to-day investment management decisions for this ETF. The team is highly experienced with respect to all aspects relating to the management of an ETF portfolio, including collateral management, OTC swap trading, adherence to UCITS regulations and counterparty exposure and monitoring.


    Reportable income


    USD Acc
    Price time
    16:00 EST (NY)

    Further details

    Charges and tax

    ISA eligible
    SIPP eligible
    UK Fund Reporting Status

    Management / administration

    Legal & General UCITS ETF Plc
    Depositary and Trustee
    The Bank of New York Mellon SA/NV, Dublin Branch
    Securities regulator
    Central Bank of Ireland

    Country registration

    This share class is registered for sale in the following countries:


    ExchangeCurrencyTickerListing dateISINBloomberg codeReuters codeTrading hours (local)
    London Stock ExchangeGBPBIGT23/01/2018IE00BF0H7608BIGT LNBIGT.L08:00 - 16:30
    London Stock ExchangeUSDBIOT23/01/2018IE00BF0H7608BIOT LNGEBIOT.L08:00 - 16:30
    Borsa ItalianaEURBIOT23/02/2018IE00BF0H7608BIOT IMECBIOT.MI09:00 - 17:30
    Deutsche BörseEURETLI06/02/2018IE00BF0H7608ETLI GYETLI.DE09:00 - 17:30
    EuronextEURBIOT01/02/2018IE00BF0H7608BIOT NAGOBIOT.AS09:00 - 17:30
    SIX Swiss ExchangeCHFBIOT05/06/2020IE00BF0H7608BIOT SWBIOTC.S09:00 - 17:30

    Key risks

    The value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested.

    Past performance is not a guide to the future.

    An investment in the ETF involves a significant degree of risk. Any decision to invest should be based on the information contained in the relevant prospectus. Prospective investors should obtain their own independent accounting, tax and legal advice and should consult their own professional advisers to ascertain the suitability of the ETF as an investment.

    The value of the shares in the ETF is directly affected by increases and decreases in the value of the Index. Accordingly the value of a share in the ETF may go up or down and a shareholder may lose some or the entire amount invested.

    The ETF's ability to closely track the Index will be affected by its ability to purchase and/or sell the Index constituents and any legal or regulatory restrictions or disruptions affecting them.

    The ETF's ability to closely track the Index will also be affected by transaction costs and taxes incurred when adjusting its investment portfolio generally and/or to mirror any periodic adjustments to the constituents of the Index. There can be no certainty that ETF shares can always be bought or sold on a stock exchange or that the market price at which the ETF shares may be traded on a stock exchange will reflect the performance of the Index.

    The ETF is subject to the risk that third party service providers (such as a bank entering into swaps with the ETF or the ETF's depositary) may go bankrupt or fail to pay money due to the ETF or return property belonging to the ETF.

    As the Index includes micro, small and medium-sized publicly traded companies, the ETF is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole.

    Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production as a result of: (i) clinical trial failures, (ii) governmental intervention or refusal to grant appropriate approvals and/or licenses for clinical trials or commercial production and/or (iii) a lack of commercially viability. Additionally, the emergence of cheaper or more effective drugs could lead to a decline in the revenues of such companies. Such factors could lead to a decline in the value of the companies represented in the Index and therefore the ETF.

    For more information, please refer to the key investor information document.

    Important information

    Issued by LGIM Managers (Europe) Limited as management company for this fund. Registered in Ireland No. 609677. Registered Office: 33/34 Sir John Rogerson’s Quay, Dublin, 2, Ireland. Authorised and Regulated by the Central Bank of Ireland No. C173733.

    GO ETF Solutions LLP has been appointed as the discretionary investment manager for this Fund, it is authorised and regulated by the Financial Conduct Authority No.477266.

    We are a member of the Irish Funds Association.

    All features described on this website are those current at the time of publication and may be changed in the future. Nothing on this website should be construed as advice and it is therefore not a recommendation to buy or sell securities. If in doubt about the suitability of this product, you should seek professional advice. Copies of the prospectus, key investor information document, annual and semi-annual reports & accounts are available free of charge on request or at

    This website is only directed at investors resident in jurisdictions where our funds are registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.

    Source and third party data

    Source: Unless otherwise indicated all data contained on this website is sourced from Legal & General Investment Management Limited.

    Where this document contains third party data ('Third Party Data’), we cannot guarantee the accuracy, completeness or reliability of such Third Party Data and accept no responsibility or liability whatsoever in respect of such Third Party Data

    Index disclaimer

    The L&G Pharma Breakthrough UCITS ETF (the “ETF”) is not sponsored, promoted, sold or supported by Solactive AG. Nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index price, at any time or in any other respect.

    The Solactive Pharma Breakthrough Value Index (the “Index”) is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Legal & General UCITS ETF Plc, Solactive AG has no obligation to point out errors in the Index to third parties including, but not limited to, investors and/or financial intermediaries of the ETF. Solactive AG does not guarantee the accuracy and/or the completeness of the Index or any related data, and shall not have any liability for any errors, omissions or interruptions therein.

    Neither publication of the Index by Solactive AG, nor the licensing of the Index or Index trade mark, for the purpose of use in connection with the ETF, constitutes a recommendation by Solactive AG to invest capital in said ETF nor does it, in any way, represent an assurance or opinion of Solactive AG with regard to any investment in this ETF. In no event shall Solactive AG have any liability for any lost profits or indirect, punitive, special or consequential damages or losses, even if notified of the possibility thereof.